References
- Cuneo BF, Strasburger JF. Management strategy for fetal tachycardia. Obstet Gynecol. 2000;96:575–581.
- Jaeggi ET, Carvalho JS, De Groot E, et al. Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. Circulation. 2011;124(16):1747–1754.
- Zhou K, Zhou R, Zhu Q, et al. Evaluation of therapeutic effect and cytokine change during transplacental digoxin treatment for fetal heart failure associated with fetal tachycardia, a case-control. Study Int J Cardiol. 2013;169(4):e62–e64.
- Ito S. Transplacental treatment of fetal tachycardia: implications of drug transporting proteins in placenta. Semin Perinatol. 2001;25(3):196–201.
- Tasnif Y, Morado J, Hebert MF. Pregnancy-related pharmacokinetic changes. Clin Pharmacol Ther. 2016;100(1):53–62.
- Azzazy HM, Duh SH, Maturen A, et al. Multicenter study of Abbott AxSYM® Digoxin II assay and comparison with 6 methods for susceptibility to digoxin-like immunoreactive factors. Clin Chem. 1997;43(9):1635–1640.
- Lampon N, Pampin F, Tutor JC. Investigation of possible interference by digoxin-like immunoreactive substances on the Architect iDigoxin CMIA in serum samples from pregnant women, and patients with liver disease, renal insufficiency, critical illness, and kidney and liver transplant. Clin Lab. 2012;58(11–12):1301–1304.
- Saul JP, Cain NB. Can we do a prospective trial for fetal tachycardia?: the barriers to clinical trials in small patient populations. Circulation. 2011;124(16):1703–1705.
- Husain A, Hubail Z, Al Banna R. Fetal supraventricular tachycardia, treating the baby by targeting the mother. BMJ Case Rep. 2013;2013:bcr2012008515.
- Perles Z, Gavri S, Rein A. Tachyarrhythmias in the fetus: state of the art diagnosis and treatment. Prog Pediatr Cardiol. 2006;22(1):95–107.
- Hebert M, Easterling T, Kirby B, et al. Effects of Pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther. 2008;84(2):248–253.
- Luxford AM, Kellaway GS. Pharmacokinetics of digoxin in pregnancy. Eur J Clin Pharmacol. 1983;25(1):117–121.
- Lee LS, Chan LN. Evaluation of a sex-based difference in the pharmacokinetics of digoxin. Pharmacotherapy. 2006;26(1):44–50.
- Koup JR, Greenblatt DJ, Jusko WJ, et al. Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. J Pharmacokinet Biopharm. 1975;3(3):181–192.
- Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokine Biopharm. 1977;5(5):445–479.
- Costantine MM. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol. 2014;5(Article):65.
- Patel D, Cuneo B, Viesca R, et al. Digoxin for the treatment of fetal congestive heart failure with sinus rhythm assessed by cardiovascular profile score. J Matern Fetal Neonatal Med. 2008;21(7):477–482.
- Muniswaran G, Japaraj RP, Asri RAR, et al. Intrauterine management of fetal supraventricular tachycardia (SVT) with cardiac failure.Med. J Malaysia. 2015;70(6):371–372.
- Zhou KY, Hua YM, Zhu Q. Transplacental digoxin therapy for fetal atrial flutter with hydrops fetalis. World J Pediatr. 2011;8(3):275–277.
- Suri V, Keepanaseril A, Aggarwal N, et al. Prenatal management with digoxin and sotalol combination for fetal supraventricular tachycardia: case report and review of literature. Indian J Med Sci. 2009;63(9):411–414.
- Van Hasselt JGC, Andrew MA, Hebert MF, et al. The status of pharmacometrics in pregnancy: highlights from the 3rdAmerican conference on pharmacometrics. Br J Clin Pharmacol. 2012;74(6):932–939.
- Strasburger JF, Cheulkar B, Wichman HJ. Perinatal arrhythmias: diagnosis and management. Clin Perinatol. 2007;34(4):627–652.